Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2012-04-03 | Genfit (France) | €600 K | private placement | Yorkville Advisors LLC (USA) | Cardiovascular diseases - Metabolic diseases - Liver diseases | Private placement |
2012-03-30 | Immunogenes (Switzerland - Hungary) | CHF 1 million (€0.83 million) | financing round | LSWorks LLC (USA) PolyTechnos Venture Partners (Germany) majority of the company’s existing investors |
Technology - Services | Fundraising |
2012-03-29 | Thrombogenics (Belgium) | €77.8 million | private placement | domestic and international investors - undisclosed qualified institutional buyers in the United States | Ophtalmological diseases | Private placement |
2012-03-28 | Promethera Biosciences (Belgium) | € 23.6 million ($31.4 million) | series B financing round | Boehringer Ingelheim Venture Fund (Germany) Shire (UK) Mitsui Global Investment (Japan) ATMI (USA) SambrInvest (Belgium) Walloon Region (Belgium) |
Regenerative medicine - Liver diseases | Fundraising |
2012-03-28 | DBV Technologies (France) | €40.5 million | initial public offering (IPO) | The French Strategic Investment Fund (Fonds stratégique d\'investissement - FSI) has taken a stake in DBV Technologies by investing 15 € million euros as part of the offer. The FSI is holding 12.6%% of its capital. | Allergic diseases - Immunological diseases | IPO |
2012-03-26 | ADC Therapeutics (Switzerland) | $50 million (€37.4 million) | fundraising | Celtic Therapeutics (USA-UK-Switzerland) - co-founders of Spirogen (UK) - Cancer Research Technology (UK) | Cancer - Oncology | Fundraising |
2012-03-22 | Enterome Bioscience (France) | €5 million | series A financing round | Seventure Partners (France) - Lundbeckfond Ventures (Denmark) | Digestive diseases - Inflammatory diseases | Fundraising |
2012-03-21 | Novasep (France) | € 33 million | private placement | FSI (France) - Azulis (France) | Technology - Services | Private placement |
2012-03-13 | Hybrigenics (France) | € 3.3 million | private placement | Cancer - Oncology - Technology - Services | Private placement | |
2012-03-06 | Numab (Switzerland) | CHF 895 000 (€ 742 604) | grant | Swiss Commission for Technology and Innovation (CTI) (Switzerland) | Grant | |
2012-03-06 | Telormedix (Switzerland) | CHF 1.37 Million | grant | CTI/KTI Programme (Switzerland) | Cancer - Oncology - Inflammatory diseases | Grant |
2012-03-06 | Lanthio Pharma (The Netherlands) | €180,000 | grant | European Eurostars Programme (EU) | Technology - Services | Grant |
2012-03-05 | Medicyte (Germany) PRIMACYT (Germany) | €300 000 | grant | Federal Ministry of Education and Research (BMBF) (Germany) | Regenerative medicine - Liver diseases | Grant |
2012-03-05 | Exonhit (France) | €418,000 | grant | Cancer - Oncology | Grant | |
2012-03-05 | AB Science (France) | €10 million | Cancer - Oncology - Autoimmune diseases - Neurodegenerative diseases | Establishment of a new subsidiary in the EU | ||
2012-02-28 | BiolineRx (Israel) | $15 million (€ 11.2 million) | private placement | healthcare-focused U.S. institutional investors | Private placement | |
2012-02-16 | Protalix (Israel) | $24.75 million (€18.8 million) | private placement | Rare diseases - Genetic diseases | Private placement | |
2012-02-14 | Adocia (France) | € 25.3 million (increased to €27.36 million following partial exercise of over-allotment option) | IPO | Metabolic diseases | IPO | |
2012-02-13 | Innavirvax (France) | € 3.7 million | financing round | Pradeyrol Développement(France) Fa Dièse (France) FRCI (Fonds Régional de Co-Investissement d’Ile-de-France) (France) Cap Decisif 2 (France) G1J (France) |
Infectious diseases | Fundraising |
2012-02-13 | Effimune (formerly TcL Pharma) (France) and the TRIAD consortium | €3 million | grant | Autoimmune diseases | Grant |